Anti-Glucose Transporter GLUT1 抗体 [EPR3915] (ab115730)

ab115730 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab115730 は 7 報の論文で使用されています。

  • Shi S  et al. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Lett 360:227-33 (2015). WB ; Human . PubMed: 25687883
  • Qin W  et al. Inhibition of autophagy promotes metastasis and glycolysis by inducing ROS in gastric cancer cells. Oncotarget 6:39839-54 (2015). WB ; Human . PubMed: 26497999
  • Boyer-Di Ponio J  et al. Instruction of circulating endothelial progenitors in vitro towards specialized blood-brain barrier and arterial phenotypes. PLoS One 9:e84179 (2014). WB . PubMed: 24392113
  • Saucillo DC  et al. Leptin metabolically licenses T cells for activation to link nutrition and immunity. J Immunol 192:136-44 (2014). PubMed: 24273001
  • Caro-Maldonado A  et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J Immunol 192:3626-36 (2014). PubMed: 24616478
  • Cao Y  et al. Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells. PLoS One 9:e104104 (2014). WB ; Mouse . PubMed: 25090630
  • Foster R  et al. Multiple Metabolic Alterations Exist in Mutant PI3K Cancers, but Only Glucose Is Essential as a Nutrient Source. PLoS One 7:e45061 (2012). WB . PubMed: 23028762

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"